---
schema_version: "secwatch.filing_event.v1"
accession: "0000313143-22-000042"
form_type: "8-K"
ticker: "HAE"
cik: "0000313143"
company_name: "HAEMONETICS CORP"
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:40:00.164705+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Haemonetics enters amended credit agreement: $280M term loan, $420M revolver, maturity extended to June 2025

## Summary
- New $420M revolving credit facility (up from $350M) and $280M term loan to replace existing term loan.
- Maturity extended by two years to June 15, 2025; quarterly amortization begins at 2.5% then 5%.
- Interest: Adjusted Term SOFR plus 1.125%–1.750% credit spread based on leverage ratio.
- Financial covenants: max leverage 3.50x (4.00x post-acquisition), min interest coverage 4.00x.

## SEC filing metadata
- accession: 0000313143-22-000042
- form_type: 8-K
- ticker: HAE
- cik: 0000313143
- company_name: HAEMONETICS CORP
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313143/000031314322000042/0000313143-22-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313143/000031314322000042/hae-20220726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000313143-22-000042
- JSON: https://secwatch.observer/filing/0000313143-22-000042.json
- Plain text: https://secwatch.observer/filing/0000313143-22-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.